{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:26:24Z","timestamp":1787667984326,"version":"build-2736575974"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Cardiac sarcoidosis (CS) is a potentially life-threatening condition, and\n                      <jats:sup>18<\/jats:sup>\n                      F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is highly sensitive for detecting myocardial inflammation. However, corticosteroid therapy may alter myocardial metabolism, complicating the interpretation of FDG PET. This study aimed to evaluate the impact of corticosteroid therapy on physiological myocardial FDG uptake and assess the utility of fasting plasma glucose (FPG) and free fatty acids (FFA) in distinguishing physiological from pathological uptake.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed FDG PET\/CT scans of 40 CS patients who underwent paired scans before and after corticosteroid therapy, following prolonged fasting (&gt;\u200918\u00a0h). The frequency of physiological myocardial FDG uptake was compared, and FPG and FFA levels were assessed as predictors using receiver operating characteristic (ROC) analysis. Exploratory analyses were also performed to assess metabolic changes across different levels of corticosteroid exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Physiological myocardial FDG uptake significantly increased after corticosteroid therapy (from 2.5% to 15%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.048). Post-treatment FFA levels were significantly lower, while FPG levels were higher. An FFA cutoff of 615 \u00b5Eq\/L predicted physiological uptake with 100% sensitivity and 83.6% specificity (AUC\u2009=\u20090.96,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), whereas FPG showed poor discrimination (AUC\u2009=\u20090.43,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.83). Patients with physiological uptake had significantly lower FFA levels; FPG did not differ between groups. In analyses stratified by corticosteroid dose, physiological uptake was less frequently observed at lower dose levels, accompanied by relatively preserved metabolic parameters.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Corticosteroid therapy increases physiological myocardial FDG uptake in CS patients, likely due to reduced FFA levels and altered metabolism. FFA may serve as a useful marker for distinguishing physiological FDG uptake from abnormal uptake, supporting more accurate PET interpretation during corticosteroid therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12149-026-02222-z","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T06:33:48Z","timestamp":1778481228000},"page":"1053-1062","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interpretation of myocardial FDG uptake during corticosteroid therapy in cardiac sarcoidosis evaluation with 18F-FDG PET\/CT"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8518-8441","authenticated-orcid":false,"given":"Osamu","family":"Manabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Aikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Magota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichizo","family":"Tsujino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Oyama-Manabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"issue":"11","key":"2222_CR1","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJMra2101555","volume":"385","author":"M Drent","year":"2021","unstructured":"Drent M, Crouser ED, Grunewald J. Challenges of Sarcoidosis and Its Management. N Engl J Med. 2021;385(11):1018\u201332. https:\/\/doi.org\/10.1056\/NEJMra2101555.","journal-title":"N Engl J Med"},{"issue":"3","key":"2222_CR2","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1055\/s-0034-1376889","volume":"35","author":"JP Lynch","year":"2014","unstructured":"Lynch JP 3rd, Hwang J, Bradfield J, Fishbein M, Shivkumar K, Tung R. Cardiac involvement in sarcoidosis: evolving concepts in diagnosis and treatment. Semin Respir Crit Care Med. 2014;35(3):372\u201390. https:\/\/doi.org\/10.1055\/s-0034-1376889.","journal-title":"Semin Respir Crit Care Med"},{"issue":"1","key":"2222_CR3","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s12350-013-9828-6","volume":"21","author":"MT Osborne","year":"2014","unstructured":"Osborne MT, Hulten EA, Singh A, Waller AH, Bittencourt MS, Stewart GC, Hainer J, Murthy VL, Skali H, Dorbala S, Di Carli MF, Blankstein R. Reduction in \u00b9\u2078F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol. 2014;21(1):166\u201374. https:\/\/doi.org\/10.1007\/s12350-013-9828-6.","journal-title":"J Nucl Cardiol"},{"issue":"9","key":"2222_CR4","doi-asserted-by":"publisher","first-page":"804","DOI":"10.3348\/kjr.2025.0148","volume":"26","author":"N Oyama-Manabe","year":"2025","unstructured":"Oyama-Manabe N, Manabe O, Aikawa T, Sobue Y, Asakura R. Updates on Cardiac MRI and PET Imaging for the Diagnosis and Monitoring of Cardiac Sarcoidosis. Korean J Radiol. 2025;26(9):804\u201316. https:\/\/doi.org\/10.3348\/kjr.2025.0148.","journal-title":"Korean J Radiol"},{"issue":"2","key":"2222_CR5","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s12350-015-0226-0","volume":"23","author":"O Manabe","year":"2016","unstructured":"Manabe O, Yoshinaga K, Ohira H, Masuda A, Sato T, Tsujino I, Yamada A, Oyama-Manabe N, Hirata K, Nishimura M, Tamaki N. The effects of 18-h fasting with low-carbohydrate diet preparation on suppressed physiological myocardial (18)F-fluorodeoxyglucose (FDG) uptake and possible minimal effects of unfractionated heparin use in patients with suspected cardiac involvement sarcoidosis. J Nucl Cardiol. 2016;23(2):244\u201352. https:\/\/doi.org\/10.1007\/s12350-015-0226-0.","journal-title":"J Nucl Cardiol"},{"issue":"9","key":"2222_CR6","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s00259-011-1832-y","volume":"38","author":"H Ohira","year":"2011","unstructured":"Ohira H, Tsujino I, Yoshinaga K. (1)(8)F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis. Eur J Nucl Med Mol Imaging. 2011;38(9):1773\u201383. https:\/\/doi.org\/10.1007\/s00259-011-1832-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2222_CR7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00259-015-3181-8","volume":"43","author":"H Ohira","year":"2016","unstructured":"Ohira H, Birnie DH, Pena E, Bernick J, Mc Ardle B, Leung E, Wells GA, Yoshinaga K, Tsujino I, Sato T, Manabe O, Oyama-Manabe N, Nishimura M, Tamaki N, Dick A, Dennie C, Klein R, Renaud J, deKemp RA, Ruddy TD, Chow BJ, Davies R, Hessian R, Liu P, Beanlands RS, Nery PB. Comparison of (18)F-fluorodeoxyglucose positron emission tomography (FDG PET) and cardiac magnetic resonance (CMR) in corticosteroid-naive patients with conduction system disease due to cardiac sarcoidosis. Eur J Nucl Med Mol Imaging. 2016;43(2):259\u201369. https:\/\/doi.org\/10.1007\/s00259-015-3181-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2222_CR8","doi-asserted-by":"publisher","first-page":"102082","DOI":"10.1016\/j.nuclcard.2024.102082","volume":"43","author":"C Rojulpote","year":"2025","unstructured":"Rojulpote C, Bhattaru A, Patil S, Adams SL, Salas JA, Vidula MK, Perez RP, Kc W, Patterson K, Clancy CB, Rossman M, Goldberg L, Bravo PE. Assessing the effect of repeat positron emission tomography imaging on treatment response and cardiovascular outcomes among a homogenously treated cohort of patients with suspected cardiac sarcoidosis. J Nucl Cardiol. 2025;43:102082. https:\/\/doi.org\/10.1016\/j.nuclcard.2024.102082.","journal-title":"J Nucl Cardiol"},{"issue":"2","key":"2222_CR9","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1677\/JOE-08-0054","volume":"197","author":"DP Macfarlane","year":"2008","unstructured":"Macfarlane DP, Forbes S, Walker BR. Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J Endocrinol. 2008;197(2):189\u2013204. https:\/\/doi.org\/10.1677\/JOE-08-0054.","journal-title":"J Endocrinol"},{"issue":"11","key":"2222_CR10","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1253\/circj.CJ-19-0508","volume":"83","author":"F Terasaki","year":"2019","unstructured":"Terasaki F, Azuma A, Anzai T, Ishizaka N, Ishida Y, Isobe M, Inomata T, Ishibashi-Ueda H, Eishi Y, Kitakaze M, Kusano K, Sakata Y, Shijubo N, Tsuchida A, Tsutsui H, Nakajima T, Nakatani S, Horii T, Yazaki Y, Yamaguchi E, Yamaguchi T, Ide T, Okamura H, Kato Y, Goya M, Sakakibara M, Soejima K, Nagai T, Nakamura H, Noda T, Hasegawa T, Morita H, Ohe T, Kihara Y, Saito Y, Sugiyama Y, Morimoto SI, Yamashina A, Group JCSJW. JCS 2016 Guideline on Diagnosis and Treatment of Cardiac Sarcoidosis\u3000- Digest Version. Circ J. 2019;83(11):2329\u201388. https:\/\/doi.org\/10.1253\/circj.CJ-19-0508.","journal-title":"Circ J"},{"issue":"8","key":"2222_CR11","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.2967\/jnumed.116.187203","volume":"58","author":"H Ohira","year":"2017","unstructured":"Ohira H, Ardle BM, deKemp RA, Nery P, Juneau D, Renaud JM, Klein R, Clarkin O, MacDonald K, Leung E, Nair G, Beanlands R, Birnie D. Inter- and Intraobserver Agreement of (18)F-FDG PET\/CT Image Interpretation in Patients Referred for Assessment of Cardiac Sarcoidosis. J Nucl Med. 2017;58(8):1324\u20139. https:\/\/doi.org\/10.2967\/jnumed.116.187203.","journal-title":"J Nucl Med"},{"issue":"7","key":"2222_CR12","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.hrthm.2014.03.043","volume":"11","author":"DH Birnie","year":"2014","unstructured":"Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, Judson MA, Kron J, Mehta D, Cosedis Nielsen J, Patel AR, Ohe T, Raatikainen P, Soejima K. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart rhythm: official J Heart Rhythm Soc. 2014;11(7):1305\u201323. https:\/\/doi.org\/10.1016\/j.hrthm.2014.03.043.","journal-title":"Heart rhythm: official J Heart Rhythm Soc"},{"issue":"9","key":"2222_CR13","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1093\/ehjci\/jev142","volume":"16","author":"NR Aggarwal","year":"2015","unstructured":"Aggarwal NR, Snipelisky D, Young PM, Gersh BJ, Cooper LT, Chareonthaitawee P. Advances in imaging for diagnosis and management of cardiac sarcoidosis. Eur Heart J Cardiovasc Imaging. 2015;16(9):949\u201358. https:\/\/doi.org\/10.1093\/ehjci\/jev142.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"1","key":"2222_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s12149-023-01878-1","volume":"38","author":"N Tamaki","year":"2024","unstructured":"Tamaki N, Manabe O. Current status and perspectives of nuclear cardiology. Ann Nucl Med. 2024;38(1):20\u201330. https:\/\/doi.org\/10.1007\/s12149-023-01878-1.","journal-title":"Ann Nucl Med"},{"issue":"5","key":"2222_CR15","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s12350-014-9901-9","volume":"21","author":"A Ahmadian","year":"2014","unstructured":"Ahmadian A, Brogan A, Berman J, Sverdlov AL, Mercier G, Mazzini M, Govender P, Ruberg FL, Miller EJ. Quantitative interpretation of FDG PET\/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis. J nuclear cardiology: official publication Am Soc Nuclear Cardiol. 2014;21(5):925\u201339. https:\/\/doi.org\/10.1007\/s12350-014-9901-9.","journal-title":"J nuclear cardiology: official publication Am Soc Nuclear Cardiol"},{"issue":"1","key":"2222_CR16","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1152\/physrev.00015.2009","volume":"90","author":"GD Lopaschuk","year":"2010","unstructured":"Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010;90(1):207\u201358. https:\/\/doi.org\/10.1152\/physrev.00015.2009.","journal-title":"Physiol Rev"},{"key":"2222_CR17","doi-asserted-by":"publisher","unstructured":"Ayyala US, Nair AP, Padilla ML. Cardiac sarcoidosis. Clinics in chest medicine. 2008;29(3):493\u2013508, ix. https:\/\/doi.org\/10.1016\/j.ccm.2008.03.005","DOI":"10.1016\/j.ccm.2008.03.005"},{"issue":"1","key":"2222_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ahj.2008.09.009","volume":"157","author":"JS Kim","year":"2009","unstructured":"Kim JS, Judson MA, Donnino R, Gold M, Cooper LT Jr., Prystowsky EN, Prystowsky S. Cardiac sarcoidosis. Am Heart J. 2009;157(1):9\u201321. https:\/\/doi.org\/10.1016\/j.ahj.2008.09.009.","journal-title":"Am Heart J"},{"issue":"9","key":"2222_CR19","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/S0002-9149(01)01978-6","volume":"88","author":"Y Yazaki","year":"2001","unstructured":"Yazaki Y, Isobe M, Hiroe M, Morimoto S, Hiramitsu S, Nakano T, Izumi T, Sekiguchi M. Central Japan Heart Study G. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88(9):1006\u201310.","journal-title":"Am J Cardiol"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02222-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-026-02222-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02222-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:43:16Z","timestamp":1787665396000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-026-02222-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2222"],"URL":"https:\/\/doi.org\/10.1007\/s12149-026-02222-z","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Approval from our institutional ethics review board was obtained, and the requirement for informed consent was waived for this retrospective study.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}